PAVmed Inc. (PAVM)

Market Cap	10.93M
Revenue (ttm)	3.83M
Net Income (ttm)	-67.35M
Shares Out	10.41M
EPS (ttm)	-8.08
PE Ratio	n/a
Forward PE	1.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,274
Open	1.030
Previous Close	1.040
Day's Range	1.020 - 1.080
52-Week Range	0.600 - 4.875
Beta	0.69
Analysts	Strong Buy
Price Target	21.00 (+1,900.0%)
Earnings Date	Nov 13, 2024

About PAVM

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 28, 2016
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: PAVM
• Website: https://www.pavmed.com

Financial Performance

In 2023, PAVmed's revenue was $2.45 million, an increase of 550.40% compared to the previous year's $377,000. Losses were -$66.27 million, -25.76% less than in 2022.

Analyst Forecast

According to one analyst, the rating for PAVM stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target

$21.0

(1,900.00% upside)

Analyst Consensus: Strong Buy